Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acromegaly
Study findings from University of Naples broaden understanding of acromegaly
March 2nd, 2008
Researchers in Naples, Italy conducted a study "To evaluate the efficacy of dose escalation of Octreotide-long-acting repeatable (LAR) up to 40 mg/month we studied 56 newly diagnosed patients with acromegaly (24 women, 32 men; age 20-82 years). Analytical, observational, open and prospective." "Three months after LAR treatment beginning with a dose of 20 mg /q28d (every 28 days), 24 patients maintained the same dose (Group A), while 32 required a dose of 30 mg/q28d (Group 13). The dose was further increased to 40 mg/q28d in 17 out of the 32 patients of GroupB for another 12 months (Group C). After 24 months, serum GH and IGF-I levels decreased by 93.1 +/- 8.6% (95%...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-02)
|
